GleamWall
中文EN

BDSX BIODESIX INC

Services-Medical Laboratories · Nasdaq · SEC CIK 1439725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.2%
TTM net income YoY31.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-18.7%
Net margin-25.7%
FCF margin-18.1%
EBITDA margin-13.4%

Returns

ROE-778.9%
ROA-29.6%
ROIC (approx.)-50.2%
Asset turnover1.15x

Leverage & solvency

Liabilities / assets90.8%
Debt / equity5.76x
Current ratio2.96x
Interest coverage-2.45x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$24.04M$26.86M$25.55M$28.75M$21.77M$20.02M$17.96M$20.43M
R&D expense$2.99M$3.13M$3.29M$2.87M$2.99M$3.27M$2.87M$2.41M
SG&A expense$22.50M$24.28M$24.26M$22.97M$21.71M$22.41M$20.45M$20.22M
Operating income-$6.11M-$5.39M-$6.20M-$1.97M-$7.05M-$9.72M-$9.14M-$6.65M
Interest expense$2.00M$1.98M$1.98M$2.06M$2.07M$1.90M$1.69M$1.75M
Income tax$0$0$0$0$0$0$0$0
Net income-$8.03M-$7.27M-$7.79M-$3.98M-$8.72M-$11.47M-$11.10M-$8.25M
EBITDA-$4.71M-$4.00M-$4.80M-$580,000-$5.64M-$8.28M-$7.70M-$5.20M
EPS (basic)-0.75-0.71-0.81—-1.16-1.56-1.52—
EPS (diluted)-0.75-0.71-0.81—-1.16-1.56-1.52—
Weighted avg. shares (diluted)10.66M10.30M9.66M—7.50M7.33M7.30M—
Banking
Provision for credit losses$196,000$92,000$24,000$71,000$0$8,000$101,000$434,000
Balance sheet
Cash & equivalents$28.41M$30.00M$25.57M$18.99M$16.69M$20.82M$17.69M$26.33M
Receivables$9.12M$9.11M$9.50M$9.04M$12.67M$7.45M$7.64M$8.60M
Current assets$42.13M$43.56M$40.91M$32.52M$33.40M$32.45M$29.62M$39.48M
PP&E, net$23.62M$23.80M$24.19M$24.82M$25.46M$26.14M$26.97M$27.83M
Goodwill$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M
Intangibles$2.53M$2.98M$3.45M$3.88M$4.38M$4.87M$5.36M$5.87M
Total assets$93.94M$95.33M$94.64M$87.48M$88.72M$87.74M$86.24M$97.24M
Current liabilities$14.25M$15.29M$14.49M$17.44M$18.15M$15.16M$13.32M$14.32M
Long-term debt$50.00M$50.00M$50.00M$50.01M$50.01M$50.02M$40.02M$40.03M
Total debt$50.00M$50.00M$50.00M$50.01M$50.01M$50.02M$40.02M$40.03M
Total liabilities$85.27M$86.18M$85.50M$89.94M$90.44M$86.60M$75.18M$76.37M
Shareholders' equity$8.68M$9.14M$9.13M-$2.46M-$1.72M$1.14M$11.06M$20.88M
Net debt$21.59M$20.00M$24.43M$31.02M$33.32M$29.20M$22.33M$13.69M
Shares outstanding11.05M10.55M10.11M8.25M7.95M146.58M146.44M7.27M
Cash flow statement
Operating cash flow-$7.20M-$1.56M-$10.17M$778,000-$8.88M-$6.57M-$8.60M-$4.10M
Capital expenditure$555,000$197,000$81,000$86,000$48,000$51,000$74,000$839,000
Free cash flow-$7.76M-$1.76M-$10.25M$692,000-$8.93M-$6.62M-$8.68M-$4.93M
Investing cash flow-$600,000-$254,000-$144,000-$104,000-$67,000-$95,000-$137,000-$884,000
Financing cash flow$6.22M$6.24M$16.90M$1.71M$4.82M$9.79M$97,000-$181,000
Depreciation & amortization$1.40M$1.39M$1.40M$1.39M$1.41M$1.44M$1.44M$1.45M
Stock-based compensation$852,000$820,000$1.11M$1.07M$1.05M$1.04M$972,000$1.26M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.